ROCK2 and ciliopathy: Since the newer, more selective ROCK2 inhibitors may be more promising alternatives for ciliopathy disease indications, future work should focus on preclinical studies of belumosudil or related isoquinolone derivatives as potential candidates for drug repurposing.